Aditya Humad, Acting CFO of AxioMed and Managing Partner of KICVentures, announced modifications of the terms of their previously signed 15-year exclusive license agreement. “This is very exciting for me as it was a mutually recognized opportunity to improve on the terms that make it much more favorable for us to accelerate our strategies to commercialization.”
“As the global leader in biomaterial solutions, we remain very excited about the unique application of our polymer technology in AxioMed’s Viscoelastic Disc Replacement and look forward to the long-term success and partnership for both companies in bringing such a great solution to patients globally” said Robert Brown, VP of Marketing at DSM Biomedical.
Dr. Kingsley R. Chin, Managing Partner of KICVentures and a board-certified spine surgeon believes this material will be revolutionary for other spinal applications such as facet replacement and for correcting scoliosis. “DSM Biomedical affirmed their trust in our team when they gave us a 15-year exclusive in spine when larger competitors have deeper pockets.”